Local production of pharmaceuticals in Africa and access to essential medicines: 'Urban bias' in access to imported medicines in Tanzania and its policy implications

Globalization and Health

Volumn 10, Issue 1, 2014, Pages

  Mujinja, Phares G M ^a   Mackintosh, Maureen ^b   Justin Temu, Mary ^a   Wuyts, Marc ^c,d  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b OPEN UNIVERSITY   (United Kingdom)

^c INSTITUTE OF SOCIAL STUDIES   (Netherlands)

^d REPOA   (Tanzania)

Author keywords

Access to medicines; Africa; Local production of medicines; Tanzania; Urban bias

Indexed keywords

ALBENDAZOLE; AMOXICILLIN; DIAZEPAM; DICLOFENAC; DRUG; ESSENTIAL DRUG; FOLIC ACID; IMPORTED MEDICINE; METRONIDAZOLE; PRAZIQUANTEL; PYRIMETHAMINE PLUS SULFADOXINE; UNCLASSIFIED DRUG;

DRUG PRESCRIBING; FOREIGN POLICY; HEALTH CARE; HEALTH POLICY; HEALTH SERVICES; MEDICINE; PHARMACEUTICAL INDUSTRY; POLICY APPROACH; PRICE DETERMINATION;

ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG MANUFACTURE; ECONOMIC DEVELOPMENT; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DISTRIBUTION; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; PRIORITY JOURNAL; TANZANIA; URBAN BIAS; URBAN RURAL DIFFERENCE; WORLD HEALTH ORGANIZATION; AFRICA; COMMERCIAL PHENOMENA; COST; DRUG INDUSTRY; ECONOMICS; HEALTH CARE DELIVERY; HUMAN; ORGANIZATION AND MANAGEMENT; RURAL POPULATION; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; URBAN POPULATION;

KENYA; TANZANIA;

AFRICA; COMMERCE; COSTS AND COST ANALYSIS; DRUG INDUSTRY; DRUGS, ESSENTIAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; RURAL POPULATION; TANZANIA; URBAN POPULATION; WORLD HEALTH ORGANIZATION;

EID: 84899517492     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-10-12     Document Type: Article

References (46)

1. Wexler A, Valentine A, Kates J. Donor funding for health in low- and middle-income countries 2002-2010 2010, Menlo Park Ca: Kaiser Family Foundation.
2. The Global Fund Making a Difference: Sub-Saharan Africa 2011, Geneva: The Global Fund, The Global Fund.
3. Ravishankar N, Gubbins P, Cooley JC, Leach-Kemon K, Michaud CM, Jamison DT, Murray CJL. Financing of global health: tracking development assistance for health from 1990 to 2007. Lancet 2009, 373:2113-2124. 10.1016/S0140-6736(09)60881-3, 19541038.
4. Murray CJ, Anderson B, Burstein R, Leach-Kemon K, Schneider M, Tardif A, Zhang R. Development assistance for health: trends and prospects. Lancet 2011, 378:8-10. 10.1016/S0140-6736(10)62356-2, 21481450.
5. Chaudhuri S, Mackintosh M, Mujinja PGM. Indian generics producers, access to essential medicines and local production in Africa: an argument with reference to Tanzania. Eur J Dev Res 2010, 22(4):451-468.
6. Shadlen K. The political economy of AIDS treatment: intellectual property and the transformation of generic supply. Int Stud Q 2007, 51:559-581.
7. Chien CV. HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?. PLoS ONE 2007, 2(3):e278. 10.1371/journal.pone.0000278, 1805689, 17372625.
8. Kaplan W, Laing R. Local production of pharmaceuticals: industrial policy and access to medicines: an overview of key concepts, issues and opportunities for future research. Health, nutrition and population discussion paper 2005, Washington: World Bank, January.
9. Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa - a six country study. PLoS One 2008, 3(5):e2132. 10.1371/journal.pone.0002132, 2324203, 18461128.
10. Kaplan W. Local production and access to medicines in low- and middle-income countries: a literature review and critical analysis 2011, Geneva: World Health Organization.
11. Anderson T. The tide turns for drug manufacturing in Africa. Lancet 2010, 375:1597. 10.1016/S0140-6736(10)60687-3, 20458781.
12. World Health Organization (WHO) World medicines situation 2011, Geneva: WHO, World Health Organization (WHO).
13. World Health Organization (WHO) Local production for access to medical products: developing a framework to improve public health 2011, Geneva: WHO, World Health Organization (WHO).
14. World Health Organization (WHO) Local production policy brief http://www.who.int/phi/publications/local_production_policy_brief/en/index.html accessed 27.08.2013, World Health Organization (WHO).
15. BMZ/GIZ,UNCTAD,UNIDO Local pharma production platform http://www.local-pharma-production.net/index.php?id=63 accessed 27.08.2013, BMZ/GIZ,UNCTAD,UNIDO.
16. United Nations Industrial Development Organization (UNIDO)/GTZ The viability of pharmaceutical manufacturing in Ghana to address priority endemic diseases in the West Africa sub-region 2007, Vienna: UNIDO, United Nations Industrial Development Organization (UNIDO)/GTZ.
17. GIZ Local production of pharmaceuticals in Africa and access to medicines http://www.giz.de/en/mediacenter/10647.html accessed 27.08.2013, GIZ.
18. African Union Manufacturing plan for Africa: business plan 2012, Addis Ababa: AUC-UNIDO, http://www.unido.org/fileadmin/user_media_upgrade/Resources/Publications/Pharmaceuticals/PMPA_Business_Plan_Nov2012_ebook.PDF, African Union.
19. African Union COHRED. NEPAD strengthening pharmaceutical innovation in Africa NEPAD-COHRED 2010
20. United Nations Industrial Development Organization (UNIDO) Pharmaceutical sector profile: Uganda 2010, Vienna: UNIDO, United Nations Industrial Development Organization (UNIDO).
21. South African Generic Medicines Association http://www.sagma.net/ accessed 28.08.2013, South African Generic Medicines Association.
22. World Health Organization (WHO)/Health Action International Medicines prices: a new approach to measurement 2003, Geneva: WHO/HAI, World Health Organization (WHO)/Health Action International.
23. Ministry of Health and Social Welfare Standard treatment guidelines and National Essential Medicines List (NEMLIT) for Mainland Tanzania 2007, Dar es Salaam: United Republic of Tanzania, 3, Ministry of Health and Social Welfare.
24. Chambers JM, Cleveland WS, Kleiner B, Tukey PA. Graphical methods for data analysis 1983, Pacific Grove, California: Wadsworth & Brooks/Cole Publishing, Statistics / Probability Series.
25. Lipton M. Why poor people stay poor: a study of urban bias in world development 1977, London: Temple Smith.
26. Jones GA, Corbridge S. The continuing debate about urban bias: the thesis, its critics, its influence and implications for poverty-reduction strategies. Prog Dev Stud 2010, 10(1):1-18.
27. Lipton M. Urban bias: of consequences, classes and causality. J Dev Stud 1993, 29(4):229-258.
28. Lipton M. Urban bias revisited. J Dev Stud 1984, 20(3):139-166.
29. United Republic of Tanzania (URT) Household budget survey 2007 2009, Dar es Salaam: National Bureau of Statistics, United Republic of Tanzania (URT).
30. Kruk ME, Mbaruku G, Rockers PC, Galea S. User fee exemptions are not enough: out-of-pocket payments for 'free' delivery services in rural Tanzania. Trop Med Int Health 2008, 13(12):1442-1451. 10.1111/j.1365-3156.2008.02173.x, 18983268.
31. Mackintosh M, Tibandebage P. Inclusion by design: rethinking regulatory intervention in Tanzanian health care. J Dev Stud 2002, 39(1):1-20.
32. Tibandebage P, Mackintosh M. The market shaping of charges, trust and abuse: health care transactions in Tanzania. Soc Sci Med 2005, 61:1385-1395. 10.1016/j.socscimed.2004.11.072, 16005774.
33. Mackintosh M, Mujinja PGM. Markets and policy challenges in access to essential medicines for endemic disease. J Afr Econ 2010, Supp. 3:iii166-iii200.
34. Yohana E, Kamuhabwa A, Mujinja P. Availability and affordability of anticancer medicines at the Ocean Road Cancer Institute in Dar es Salaam, Tanzania. East Afr J Public Health 2011, 8(1):52-57.
35. United Republic of Tanzania (URT) Medicine price monitor 2009, Dar es Salaam: Ministry of Health and Social Welfare, http://www.haiweb.org/medicineprices/surveys/200409TZ/sdocs/MedicinePriceMonitorJuly2009.doc, United Republic of Tanzania (URT).
36. United Republic of Tanzania (URT) Medicine price monitor 2006, Dar es Salaam: Ministry of Health and Social Welfare, http://www.haiweb.org/medicineprices/surveys/200409TZ/sdocs/Tanzania1NovDec2006.pdf, United Republic of Tanzania (URT).
37. Yadav P, Curtis K, Sekhri N. Mapping and realigning incentives in the global health supply chain. Global health forecasting working group background paper 2006, http://www.cgdev.org/doc/DemandForecasting/RealigningIncentives.pdf.
38. Alba S, Hetzel MW, Goodman C, Dillip A, Liana J, Mshinda H, Lengeler C. Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets - a provider perspective. Malar J 2010, 9:164. 10.1186/1475-2875-9-164, 2910018, 20550654.
39. Cohen JM, Sabot O, Sabot K, Gordon M, Gross I, Bishop D, Odhiambo M, Ipuge Y, Ward L, Mwita A, Goodman C. A pharmacy too far? Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based combination therapies through private drug shops. BMC Health Serv Res 2010, 10(Suppl 1):S6. 10.1186/1472-6963-10-S1-S6, 2895750, 20594372.
40. Galway L, Corbett K, Zeng L. Where are the NGOs and why? The distribution of health and development NGOs in Bolivia. Glob Health 2011, 8:38.
41. Ahmed SM, Hossain MA, Mushtaque A, Chowdhury R, Bhuiya AU. The health workforce crisis in Bangladesh: shortage, inappropriate skill-mix and inequitable distribution. Hum Resour Health 2011, 9:3. 10.1186/1478-4491-9-3, 3037300, 21255446.
42. Makwiza I, Nyirenda L, Bongololo G, Banda T, Chimzizi R, Theobald S. Who has access to counseling and testing and anti-retroviral therapy in Malawi - an equity analysis. Int J Equity Health 2009, 8:13. 10.1186/1475-9276-8-13, 2683850, 19416512.
43. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkensb HGM, Laing RO. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ 2011, 89:412-421. 10.2471/BLT.10.084327, 3099556, 21673857.
44. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2008, 373:240. 49.
45. Yadav P, Cohen JL, Alphs S, Arkedis J, Larson PS, Massaga J, Sabo O. Trends in availability and prices of subsidized ACT over the first year of the AMFm: evidence from remote regions of Tanzania. Malar J 2012, 11:299. 10.1186/1475-2875-11-299, 3502171, 22929587.
46. Ministry of Health and Social Welfare with Ifakara Health Institute Midterm analytical review of the health sector strategic plan 2009-2015 2013, Dar es Salaam: Ministry of Health and Social Welfare, Ministry of Health and Social Welfare with Ifakara Health Institute.